How Many People Have Died From Lyme Disease?

Confirmed deaths directly caused by Lyme disease are remarkably rare. A CDC-led review of every U.S. death certificate that listed Lyme disease as a cause of death over a five-year period found that only one out of 114 records was actually consistent with the disease’s known clinical features. That does not mean Lyme is harmless, but it does mean the infection itself almost never kills. The fuller picture, however, is more complicated: Lyme disease can trigger fatal cardiac events, and the psychiatric burden it places on patients appears to raise the risk of suicide well above background rates.

What the Death Certificate Data Shows

The most rigorous attempt to count Lyme-related deaths in the United States examined all death records from 1999 through 2003 in which Lyme disease appeared as either the underlying cause or a contributing cause of death. Out of roughly 12 million deaths recorded over that period, 114 certificates mentioned Lyme disease. Researchers then reviewed each one individually. Of those 114, only a single record was consistent with what Lyme disease actually does to the body. The rest were either misattributed, listed Lyme alongside an unrelated terminal illness, or described conditions that did not match the known pathology of Borrelia burgdorferi infection.¹

This matters because death certificates are the primary data source for public health mortality statistics. If Lyme disease is being written onto certificates when it is not the true cause, any raw count overestimates the toll. But the reverse is also possible: because Lyme carditis and other fatal complications are poorly recognized, some genuine Lyme deaths may never get coded as such. The researchers behind the autopsy studies discussed below have argued exactly this point.

European Data and the “Does Not Cause Death” Claim

European epidemiologists have historically taken a blunt position. A widely cited review of European Lyme borreliosis stated that while a small proportion of untreated cases can lead to serious long-term problems, “Lyme borreliosis alone does not cause death.”² A large Danish cohort study reinforced this by following patients diagnosed with Lyme neuroborreliosis, one of the more severe forms of the disease, and finding that their overall mortality rate was no higher than the general population’s.³

These findings are reassuring at a population level: if you are diagnosed and treated for Lyme disease, your life expectancy is not shortened in a statistically detectable way. But population-level averages can mask individual catastrophes, and the autopsy literature tells a different story for a small number of patients.

Lyme Carditis and Sudden Cardiac Death

The most well-documented mechanism by which Lyme disease kills is cardiac involvement. Borrelia burgdorferi has a marked tropism for heart tissue, meaning the spirochete has an affinity for burrowing into the cardiac interstitium. When it does, the resulting inflammation can disrupt the heart’s electrical conduction system and, in extreme cases, trigger a fatal arrhythmia.

A detailed autopsy study of five patients who died suddenly from Lyme carditis found a consistent pattern. Deaths occurred from late summer into fall, the patients ranged from young adults to people in their late 40s, and four out of five were men. Pathologists found widespread inflammation across all layers of the heart, with spirochetes nestled among collagen fibers in the cardiac tissue. The researchers concluded that sudden cardiac death from Lyme disease “might be an under-recognized entity.”⁴ A separate case report echoed these findings, noting that while Lyme carditis is much less common than coronary artery disease as a cause of sudden death, it can kill through arrhythmia driven by inflammation or tissue destruction in the heart’s conduction nodes.⁵

The under-recognition problem is real. In routine autopsies, the specific conduction-system dissection needed to identify Lyme carditis is not always performed. A young person who dies suddenly in August with no known cardiac history might be attributed to a channelopathy, an undiagnosed structural defect, or simply listed as “sudden unexplained death.” Unless someone thinks to test cardiac tissue for Borrelia, the cause goes unrecorded. No one knows how often this happens, which means the true number of Lyme carditis deaths is genuinely uncertain.

Other Fatal Complications

Beyond the heart, Lyme disease has caused death through at least two other pathways, though both are exceptionally rare.

One documented case involved a 67-year-old woman who developed a cough, fever, rash, and muscle inflammation. Despite two months of antibiotic and steroid treatment, she progressed to fatal acute respiratory distress syndrome, which her physicians attributed to her Lyme infection.⁶ Cases like these are vanishingly uncommon and tend to involve older patients or those with compromised immune systems.

Neurological Lyme disease, or neuroborreliosis, can also produce severe pathology. Animal and human tissue studies have documented inflammation of the membranes covering the brain and spinal cord, vasculitis, destruction of spinal cord tissue, and degeneration of nerve cells in the dorsal root ganglia.⁷ While most patients with neuroborreliosis recover with treatment, and the Danish population study found no excess mortality in this group, severe untreated cases with extensive spinal cord or brainstem involvement could theoretically become life-threatening. The rarity of these outcomes means evidence is largely limited to case reports.

Cardiovascular complications from Lyme disease, particularly progressive heart block, remain a concern in the context of misdiagnosis. When Lyme-related atrioventricular block is mistaken for a primary cardiac condition, patients may not receive the antibiotics that could resolve the underlying infection, potentially allowing progression to complete heart block.⁸

The Suicide Question

If direct Lyme fatalities are rare, the indirect toll through mental health is harder to dismiss. A nationwide Danish cohort study following over 12,000 people diagnosed with Lyme borreliosis found that their rate of suicide was roughly 75% higher than the general population’s, and suicide attempts were about twice as common. The risk was most concentrated in the first three years after diagnosis, during which the suicide rate was more than double that of uninfected individuals.⁹

This was not a small study looking for anecdotal links. It used Denmark’s national health registry, which tracks every hospital contact and prescription fill for the entire population, and adjusted for pre-existing psychiatric conditions. The elevated rates of affective disorders and mental illness more broadly in the Lyme group suggest that the infection itself, or the chronic symptoms that sometimes follow it, imposes a genuine psychiatric burden.

Smaller studies have painted a similar picture from the patient side. Among people with persistent symptoms after Lyme treatment, about one in five reported suicidal ideation, and the rate climbed steeply among those with moderate-to-severe depression.¹⁰ Clinicians surveying patients with Lyme and associated diseases have reported that the infection contributed to suicidal and sometimes homicidal thinking in people with no prior psychiatric history, linked to a constellation of neuropsychiatric symptoms including explosive anger, sudden mood swings, dissociative episodes, and panic disorder.¹¹

None of this is counted in Lyme disease mortality statistics. A person who dies by suicide three years after a Lyme diagnosis will appear on a death certificate as a suicide, not as a Lyme death. Whether that is the right way to categorize it depends on your perspective, but it is worth knowing that the infection carries downstream psychiatric risk that standard mortality figures do not capture.

Pregnancy and Fetal Deaths

Lyme disease during pregnancy introduces a separate and distinct risk. A systematic review of all published cases found 12 instances of spontaneous miscarriage or fetal death and 8 newborn deaths that were associated with gestational Lyme disease. An additional 16 newborns had abnormal outcomes at birth, including respiratory distress and jaundice. The review noted limited but real evidence that Borrelia burgdorferi can cross the placenta.¹²

These numbers come from case reports accumulated over decades, not from systematic surveillance, so they cannot tell us how common adverse pregnancy outcomes are among all women who contract Lyme while pregnant. Many women are treated with antibiotics and deliver healthy babies. But the existence of documented fetal and neonatal deaths means the risk is not zero, and it represents another category of Lyme-associated mortality that falls outside standard death certificate counts.

Why Treatment Delays Make Everything Worse

Most of the fatal and near-fatal complications described above share a common thread: the infection was not treated promptly. Early Lyme disease, caught when the telltale bull’s-eye rash appears and treated with a standard course of oral antibiotics, almost never progresses to anything dangerous. The trouble starts when the diagnosis is missed.

A population-based study found that people whose treatment was delayed more than 30 days after symptom onset had more than twice the odds of developing post-treatment Lyme disease syndrome compared to those treated within that window.¹³ Post-treatment Lyme disease syndrome itself is not fatal, but it is the persistent, debilitating illness that drives the psychiatric morbidity discussed earlier and the disability burden that makes Lyme disease costly to society. A Dutch estimate put the figure at more than 1.7 disability-adjusted life years lost per patient with persisting symptoms, reflecting a substantial quality-of-life hit even when patients survive.¹⁴

Misdiagnosis has specific documented consequences. During the early months of the COVID-19 pandemic, for instance, overlapping symptom profiles and disrupted healthcare workflows led to delayed Lyme diagnoses. In one reported case, a patient whose Lyme was missed developed disseminated infection and cranial nerve palsy before the correct diagnosis was finally made.¹⁵ While that patient survived, the case illustrates how easily Lyme can slip through diagnostic cracks, particularly when other health crises dominate clinical attention.

The Jarisch-Herxheimer Reaction

One complication that occasionally alarms patients is the Jarisch-Herxheimer reaction, a temporary flare of symptoms that can occur within 24 hours of starting antibiotics for Lyme and other spirochetal infections. The reaction involves fever, chills, worsening rash, headache, and muscle pain as dying spirochetes release inflammatory molecules. In most cases it passes without intervention.¹⁶

Severe cases can involve hypotension requiring fluid resuscitation, as documented in a 31-year-old woman who became acutely ill one hour after her first dose of amoxicillin for Lyme disease.¹⁷ Case reports have also described respiratory distress, myocardial injury, and neurological complications during severe reactions.¹⁶ In Lyme disease specifically, fatal Jarisch-Herxheimer reactions are not established in the literature, though they remain a recognized risk in pregnancy and in neonates being treated for other spirochetal infections. The reaction is worth knowing about because it can mimic an allergic drug reaction and lead a patient or clinician to unnecessarily stop the antibiotics that are actually working.

Tick Coinfections and How They Complicate the Picture

Ticks that carry Borrelia burgdorferi frequently carry other pathogens at the same time, and coinfection can change the clinical picture. Babesiosis, caused by a parasite that destroys red blood cells, is the coinfection most associated with severe illness and death. A large retrospective study of babesiosis patients in the United States from 2015 to 2022 found that about 41% were coinfected with Borrelia burgdorferi. Interestingly, coinfected patients actually had lower 90-day mortality than those with babesiosis alone, with the adjusted odds of dying roughly halved in the coinfection group.¹⁸

That finding seems counterintuitive, but the researchers suggested it may reflect the fact that coinfected patients present with the recognizable symptoms of Lyme disease, prompting earlier medical attention and treatment, while babesiosis-only patients may go undiagnosed longer. Whatever the explanation, it underscores that the mortality risk from a tick bite in endemic areas is driven more by babesiosis and other coinfections than by Lyme disease itself. When a patient with a tick-borne illness dies, the fatal pathogen is far more likely to be Babesia, Anaplasma, or Ehrlichia than Borrelia.

Unproven Treatments and the Risks They Carry

An underappreciated source of harm in the Lyme disease landscape comes not from the spirochete but from unvalidated treatments. Some patient advocacy groups promote long-term intravenous antibiotics, herbal protocols, hyperthermia, and other unorthodox therapies for chronic Lyme disease. A commentary published in The Lancet Infectious Diseases noted that advocacy for such treatments has become intertwined with broader anti-science movements and that some of the proposed therapies are themselves dangerous.¹⁹

Prolonged IV antibiotic courses, for example, carry known risks of line infections, antibiotic-resistant secondary infections, and gallbladder complications. Patients who pursue these treatments are sometimes spending tens of thousands of dollars out of pocket on regimens that controlled trials have not shown to be effective, while delaying or forgoing evidence-based care for the conditions actually causing their symptoms. Although deaths directly attributable to unproven Lyme treatments are difficult to count, the existence of this treatment subculture means some fraction of Lyme-related suffering is iatrogenic rather than infectious.

Lyme disease also generates a peculiar case of coinfection with Babesia that has a treatment-interaction angle. One documented case involved a patient who developed a Jarisch-Herxheimer reaction while being treated for Lyme disease, with the clinical picture complicated by a simultaneous Babesia coinfection that was not immediately recognized.²⁰ Coinfections can mask each other, and treatment aimed at one pathogen may not cover the others, which is another reason prompt and thorough evaluation matters.